Agios Pharmaceuticals | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Agios Pharmaceuticals USD 76.25M 177.48M 2024-12
Alnylam Pharmaceuticals USD 966.43M 133.49M 2024-12
Amgen USD 11.97B 2.96B 2024-12
Arrowhead Research USD 51.79M 47.4M 2024-12
Astellas Pharma JPY 179.86B 113.13B 2024-12
AstraZeneca USD 5.49B 691M 2024-12
Bayer EUR 6.19B 1.57B 2024-12
Biogen USD 2.38B 675.8M 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Daiichi Sankyo JPY 682.15B 25.52B 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
Exelixis USD 217.37M 40.97M 2025-01
Gilead Sciences USD 9.99B 4.95B 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
Incyte USD 1.69B 383.72M 2024-12
Ionis Pharmaceuticals USD 242.08M 92.53M 2024-12
Merck USD 13.24B 1.35B 2024-12
Moderna USD 1.93B 283M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Novartis USD 11.46B 2.15B 2024-12
Pfizer USD 1.04B 49M 2024-12
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Roche Holding CHF 6.98B 2.15B 2024-12
Sarepta Therapeutics USD 1.1B 905.16M 2024-12
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Agios Pharmaceuticals Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.